A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)

Hypertriglyceridemia Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00519714
• Other study ID #: PNAI-MNA-001
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: September 2007
• Est. completion date: November 2008

Study information

• Verified date: February 2020
• Source: Montreal Heart Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study. Following a 6-8 week placebo and dietary-controlled baseline period, approximately 195 men and women with either hypertriglyceridemia or mixed hyperlipidemia with serum triglycerides (TG) > 200 mg/dl (2.26 mmol/l) will be randomized to receive either placebo, 30 mg 1-MNA or 90 mg 1-MNA three times daily for twelve weeks. Lipid and ancillary exploratory parameters will be evaluated at screening, during the baseline period, upon randomisation and throughout the 12-week active treatment period. Additionally, blood samples will be drawn at randomisation and at clinic visits during the active treatment period for sparse sampling population pharmacokinetic assessments. All blood samples for lipid assessments and glucose measurements will be collected following a 12-hour fast. Safety and tolerability will be assessed throughout the trial through the evaluation of physical exams, ECGs, routine hematology and blood chemistry testing, and adverse events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 195
• Est. completion date: November 2008
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients at least 18 years of age at the time of informed consent (women of childbearing potential must be practicing adequate contraception)

• Patients with mean serum TG > 200 mg/dl (2.26 mmol/l) and < 700 mg/dl (7.91 mmol/l) as measured at 2 sequential visits during the dietary controlled baseline period (Visits 2 and 3 or Visits 3 and 3a) and having lower level within 25% of upper level (higher value minus lower value)/higher value < 0.25)

• Patients willing and able to sign an informed consent form and follow the protocol

Exclusion Criteria:

• Patients who are pregnant or nursing

• Patients with evidence of hepatic (ALT or AST greater than 1.5 ULN, bilirubin greater than 1.5 ULN, or cirrhosis) or renal dysfunction (serum creatinine greater than 140 µmol/l, or nephrotic syndrome) as measured during the baseline phase

• Patients with uncontrolled diabetes mellitus (fasting glucose level above 11 mmol/l or HbA1C above 10%) as measured during the baseline phase

• Patients with hypothyroidism that is not treated or not stable for at least 6 months prior to study entry

• Patients with uncontrolled hypertension (systolic blood pressure above 160 mm Hg and/or diastolic blood pressure above 110 mm Hg)

• Patients with systolic blood pressure above 140 mm Hg AND three or more of the following cardiovascular risk factors:

• Current cigarette smoker

• HDL-C < 40 mg/dL (1.04 mmol/L)

• Coronary heart disease in male first degree relative < 55 years of age

• Coronary heart disease in female first degree relative < 65 years of age

• Male age 45 years or older

• Female age 55 years or older

• Patients with known hyperuricemia or with a history of gout

• Patients with an active peptic ulcer

• Patients with known coronary artery disease, cerebrovascular disease or peripheral arterial disease that has previously required PCI or surgical intervention

• Patients with known intolerance or allergy to niacin

• Patients consuming more than 10 alcoholic drinks per week

• Patients with a history of drug abuse

• Patients receiving any lipid modifying agent within 4 weeks of entry into the baseline period

• Patients participating in another clinical trial within 30 days of entry into the baseline period

• Patients considered to be non-compliant to study medication (< 80% study medication) or diet during the placebo-baseline phase

• Patients for whom the investigator determines that the study would not be appropriate

Related Conditions & MeSH terms

• Hypertriglyceridemia

Intervention

Dietary Supplement:
• 1-Methylnicotinamide (1-MNA)
Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
• Placebo
Placebo

Locations

Country	Name	City	State
Canada	Institut de Cardiologie de Montreal	Montreal	Quebec

Sponsors (23)

Lead Sponsor

Collaborator

Montreal Heart Institute

Cambridge Cardiac Care Centre, Centre de médecine genique communautaire, Clinique des maladies lipidiques de Québec, Commonwealth Medical Clinic, Diabetes Research, Vancouver General Hosp, Dr.Kim W Tan, First Line Medical Ltd, Hotel Dieu Hospital, Institut de Recherches Cliniques de Montreal, Manna Research, Maritime Research Center, MSHJ Research Associates, Omnispec clinical research Inc, Queen Elizabeth II Health Sciences Centre, Recherche Invascor Inc, Rhodin Recherche Clinique, Royal Victoria Hospital, Canada, St Michael's Hospital Health Center, St Paul's Hospital Healthy Heart Clinical Trial, St. Jerome Medical Research Inc., The Allin Clinic, The Clinical Trials Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percent change in total serum Triglycerides from baseline to end of study		12 weeks
Secondary	The percent change in total cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, high-density lipoprotein cholesterol , total apolipoprotein B , apolipoprotein A1 and TG/HDL-C ratio from baseline to end of study.		One year